Melatonin is a hormone produced by the pineal gland at night. Production is tied to the circadian cycle, but can be cut short upon exposure to certain light frequencies. It is therefore unwise to turn on a light once production begins. Night lights lacking the blue frequencies might be OK.
Melatonin receptors are found throughout the body - & notably, in the prostate. Since melatonin is produced only at night, one might wonder why its activities in the prostate need to occur during sleep, or are not needed during daylight.
Unlike other hormones in the endocrine system, there is no feedback mechanism from target tissue. With exposure to melatonin, receptors in the prostate ultimately lose sensitivity to the stimulus. Daytime use of a supplement would be self-defeating, since it would prevent the receptors from regaining sensitivity before nightfall.
The liver metabolises ~90% of an oral dose. Even so, the low doses initially available in the U.S. were too strong for some, which led to the introduction of much lower doses. Some report disturbed sleep even at the lowest dose. It seems that melatonin increases dream awareness. Not a good supplement for those who suffer from nightmares. Melatonin does not appear to affect dream content, but the dreams may appear to be more vivid.
Melatonin supplements are not sleeping pills, although many seem to think they are. There are complaints of morning grogginess, which makes no sense to me. I take 50mg each night - a dose recommended by Life Extension as part of their PCa protocol, although I haven't checked with LEF recently. I fall asleep quickly whether I take melatonin or not. I seem to sleep in two hour cycles. If I need to visit the bathroom after the first cycle, it makes no difference whether I have taken melatonin or not. I get up at 5 am feeling fully alert.
[1] Shift work & PCa.
(There are parallel BCa studies involving night nurses, etc.)
[1a] (2005 - Italy - military and civil pilots)
"Flight personnel are exposed to cosmic ionizing radiation, chemicals (fuel, jet engine exhausts, cabin air pollutants), electromagnetic fields from cockpit instruments, and disrupted sleep patterns."
"In civil pilots, {meta-standardized incidence ratio} was 1.47 ... for prostate cancer. Age (civil pilots are older than military pilots and cabin attendants) and disrupted sleep pattern (entailing hyposecretion of melatonin, which has been reported to suppress proliferative effects of androgen on prostate cancer cells) might be involved."
[1b] (2012 - Canada(
"Night work might influence cancer risk, possibly via suppression of melatonin release. In a population-based case-control study conducted in Montreal, Quebec, Canada, between 1979 and 1985, job histories, including work hours, were elicited from 3,137 males with incident cancer at one of 11 anatomic sites and from 512 controls. Compared with men who never worked at night, the adjusted odds ratios among men who ever worked at night were ... 2.77 ... for prostate cancer ..."
[2] Altered melatonin production in PCa.
[2a] First reported by Bartsch (Germany) over 30 years ago.
"Carcinoma patients showed different interhormonal correlations than all other groups. These results indicate that modulation of melatonin secretion, accompanied by changes in the pituitary hormone levels, may be related to development and growth of prostate cancer."
[2b] Bartsch again, 1992:
blah blah ... "indicating that the depression of serum melatonin in PC is due to a reduced pineal activity and is not caused by an enhanced metabolic degradation in the liver."
[2c] Bartsch, 1997:
"From a theoretical point of view substitution therapy with melatonin might be worthwhile since a progressive decline of pineal melatonin secretion is observed parallel to the growth of the primary tumor in breast and prostate cancer."
[2d] (2015 - Iceland)
"Melatonin has anticarcinogenic properties in experimental models. We undertook a case-cohort study of 928 Icelandic men without prostate cancer (PCa) nested within the Age, Gene/Environment Susceptibility (AGES)-Reykjavik cohort to investigate the prospective association between first morning-void urinary 6-sulfatoxymelatonin (aMT6s) levels and the subsequent risk for PCa, under the hypothesis that men with lower aMT6s levels have an increased risk for advanced PCa."
"We found that lower levels of aMT6s were associated with an increased risk for advanced PCa."
[3] Melatonin & resistance to GnRH analogues.
[3a] (1997 - Italy) "Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin"
(Triptorelin is a gonadotropin-releasing hormone agonist)
"Experimental and preliminary clinical studies have suggested that the pineal hormone melatonin (MLT) may stimulate hormone receptor expression on both normal and cancer cells. Moreover, MLT has appeared to inhibit the growth of some cancer cell lines, including prostate cancer, either by exerting a direct cytostatic action, or by decreasing the endogenous production of some tumor growth factors, such as prolactin (PRL) and insulin-like growth factor-1 (IGF-1). On this basis, a study was carried out to evaluate the clinical efficacy of a neuroendocrine combination consisting of the LHRH analogue triptorelin plus MLT in metastatic prostate cancer progressing on triptorelin alone."
"A decrease in PSA serum levels greater than 50% was obtained in 8/14 (57%) patients. Moreover, PSA mean concentrations significantly decreased on therapy of triptorelin plus MLT."
"Mean serum levels of both PRL and IGF-1 significantly decreased on therapy."
[4] PCa cell studies: apoptosis (cell death) or halting of the cell cycle.
[4a] (2000 - Italy)
"The pineal hormone melatonin has been shown to exert a direct oncostatic activity on neoplastic cells, particularly from breast cancer. In the present study, we evaluated the effects of melatonin on the proliferation and on the cell cycle distribution of human androgen-independent DU 145 prostate cancer cells."
"Melatonin, in physiological doses, significantly inhibited DU 145 cell proliferation and induced cell cycle withdrawal by accumulating cells in G0/G1 phase."
[4b] (2001 - Hong Kong)
"The antiproliferative action of melatonin on LNCaP tumor growth was demonstrated in vivo, and its association with mt1 receptor protein expression suggests the potential involvement of the receptor in the antitumor activity of the pineal gland hormone."
[4c] (2005 - U.S.)
"Melatonin treatment dramatically reduced the number of prostate cancer cells and stopped cell cycle progression in both LNCaP and PC3 cells. In addition, it induced cellular differentiation as indicated by obvious morphological changes and neuroendocrine biochemical parameters."
[5] Melatonin & the Androgen Receptor [AR]
[5a] (2001 - Israel - Rimler)
"The melatonin-mediated nuclear exclusion of the AR may explain the attenuation of AR activity in the prostate cancer cells. This is the first demonstration of a hormone-induced mislocalization of the AR in prostate epithelial cells and may represent a novel route for regulating AR activity."
[5b] (2002 - Israel - Rimler)
"Melatonin caused a robust exclusion of the AR from the cell nucleus to the cytoplasm. ... The exclusion was selective since melatonin had no such effect on the nuclear localization of estrogen receptors alpha (ERalpha) in these cells. Melatonin also caused nuclear exclusion of the AR in the presence of DHT. In addition, it attenuated androgen induced reporter gene activity in PC3 cells co-transfected with the human AR and AR reporter plasmids. Elevated androgen concentrations counteracted melatonin's effects. Melatonin did not decrease AR level or androgen binding in the cells. The nuclear localization of the AR is a hallmark of its cellular activity. These data point to AR nuclear exclusion as a possible mechanism to attenuate androgen responses in target tissues."
[6] PCa & visual impairment.
Light polution is ubiquitous. Men who are seriously visually impaired may be protected from its negative effects. I have no idea how the circadian rhythm operates in blind people who lack light cues, but the pineal gland seems to function well.
[6a] (2006 - Finland)
"Breast cancer risk in females decreased by degree of visual impairment, and a similar but less consistent trend was observed for prostate cancer in males. The incidence for the remaining cancers among nearly to totally blind persons was significantly higher than in average Finnish population."
"Our findings add to the suggestive epidemiological evidence for a decreased risk of hormone-related cancers in people with visual impairment and, consequently, a relationship between visible light at night and breast cancer risk. The result is strongly against the hypothesis of a systemic protective effect related lack of visible light."
[7] Melatonin & Angiogenesis.
[7a] (2009 - Korea)
"Melatonin, the main secretory product of the pineal gland, has been shown to exert an oncostatic activity in cancer cells. Recently, several studies have shown that melatonin has antiangiogenic properties. However, the mechanism by which melatonin exerts antiangiogenenic effects is not understood. Hypoxia inducible factor (HIF)-1 is a transcription factor which mediates adaptive response to changes in tissue oxygenation. ... In this study, pharmacologic concentrations of melatonin was found to inhibit expression of HIF-1 alpha protein under both normoxic and hypoxic conditions in DU145, PC-3, and LNCaP prostate cancer cells without affecting HIF-1 alpha mRNA levels. Consistent with the reduction in HIF-1 alpha protein levels, melatonin inhibited HIF-1 transcriptional activity and the release of vascular endothelial growth factor."
-Patrick
[1a] ncbi.nlm.nih.gov/pubmed/164...
[1b] ncbi.nlm.nih.gov/pubmed/230...
[2a] ncbi.nlm.nih.gov/pubmed/242...
[2b] ncbi.nlm.nih.gov/pubmed/139...
[2c] ncbi.nlm.nih.gov/pubmed/944...
[2d] ncbi.nlm.nih.gov/pubmed/251...
[3a] ncbi.nlm.nih.gov/pubmed/907...
[4a] ncbi.nlm.nih.gov/pubmed/110...
[4b] ncbi.nlm.nih.gov/pubmed/111...
[4c] ncbi.nlm.nih.gov/pubmed/153...
[5a] ncbi.nlm.nih.gov/pubmed/115...
[5b] ncbi.nlm.nih.gov/pubmed/121...